Edition:
United States

Alkermes Plc (ALKS.OQ)

ALKS.OQ on NASDAQ Stock Exchange Global Select Market

50.71USD
2:24pm EDT
Change (% chg)

$-1.31 (-2.52%)
Prev Close
$52.02
Open
$52.18
Day's High
$52.18
Day's Low
$50.71
Volume
127,839
Avg. Vol
312,930
52-wk High
$63.40
52-wk Low
$41.93

Chart for

About

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central... (more)

Overall

Beta: 2.23
Market Cap(Mil.): $7,993.23
Shares Outstanding(Mil.): 153.66
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 80.15 16.18
EPS (TTM): -- -- --
ROI: -- 3.01 14.60
ROE: -- 4.76 13.87

BRIEF-Alkermes qtrly gaap loss per share $0.28

* Qtrly revenues increased 12% year-over-year to $218.8 million

Jul 27 2017

BRIEF-Alkermes announces positive preliminary topline results

* Alkermes announces positive preliminary topline results from phase 3 antipsychotic efficacy study of ALKS 3831 for treatment of schizophrenia

Jun 29 2017

BRIEF-Alkermes announces initiation of study 217 for ALKS 5461

* Alkermes announces initiation of study 217 for ALKS 5461 for treatment of major depressive disorder

Jun 12 2017

BRIEF-Alkermes initiates phase 3 study of ALKS 3831 in young adult patients

* Alkermes announces initiation of phase 3 study of alks 3831 in young adult patients

Jun 08 2017

BRIEF-Alkermes CEO Richard Pops' 2016 total compensation was $9.6 mln vs $12.4 mln in 2015

* CEO Richard Pops' 2016 total compensation was $9.6 million versus $12.4 million in 2015 - sec filing Source text (http://bit.ly/2p9SZ48) Further company coverage:

Apr 13 2017

Competitors

Earnings vs. Estimates